Drug
Tirbanibulin clinical trials
Also written KX2-391 and Klisyri®.
- studies test it
- 18
- open now
- 4
- in phase 3
- 4
- first study started
- 2007
Keep track of what changes. Save the tirbanibulin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Combined with it in one product
- KX01
- 1
Studies by the year they started
18 studies that test it; most in 2023 (5)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 5
- Phase 3
- 4
- Phase 4
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 6
Almirall, S.A. (4) · PharmaEssentia (3) · Medical University of Graz (2) · Athenex, Inc. (2) · Austin Institute for Clinical Research (1) · Kinex Pharmaceuticals Inc. (1) · University Hospital, Lille (1) · Centre Hospitalier Universitaire de Nice (1)
Often tested with
Tested in the same studies.
Cryotherapy (1) · Paclitaxel (1)
Studies
Open first, then newest update. How each study uses tirbanibulin is read from its arms, and is right about nine times in ten.
Testing it · 18
- Tirbanubulin (Klisiry®) in the Treatment of Basal Cell CarcinomaRecruitingPhase 2Centre Hospitalier Universitaire de NiceNCT06112522Written as Tirbanibulin
- Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and ForeheadNot yet recruitingPhase 3University Hospital, LilleNCT07273656Written as Cryotherapy + Tirbanibulin
- Tirbanibulin for Pediatric WartsRecruitingPhase 4The Skin Center Dermatology GroupNCT06791525Written as Tirbanibulin ointment 1%
- Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin OintmentRecruitingPhase 1/2Bruce Robinson, MDNCT07010692Written as Tirbanibulin ointment 1%
- A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic KeratosisCompletedPhase 3Almirall, S.A.NCT06135415Written as Tirbanibulin
- KX01 Ointment Phase 1 Study in Patients With Plaque Type PsoriasisCompletedPhase 1PharmaEssentiaNCT05522816Written as KX01 0.01% (0.1 mg/g)
- A Study of Tirbanibulin on the Wellbeing of Participants With Actinic KeratosesCompletedPhase 4Almirall, S.A.NCT05741294Written as Tirbanibulin 2.5 mg ointment
- A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or ScalpActive, not recruitingPhase 4Almirall, S.A.NCT05387525Written as Tirbanibulin (Klisyri®) 10 mg/g ointment
- Proof of Concept Study to Access Superficial Basal Cell Carcinoma in AdultsCompletedPhase 2Austin Institute for Clinical ResearchNCT05713760Written as Tirbanibulin Ointment 1%
- Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the HandsWithdrawnPhase 4Medical University of GrazNCT06026358Written as Tirbanibulin
- A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or ScalpCompletedPhase 3PharmaEssentiaNCT05231044Written as KX01 ointment 1%
- A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic KeratosisCompletedPhase 3Almirall, S.A.NCT05279131Written as Tirbanibulin ointment 1%
- Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the FaceCompletedPhase 4Medical University of GrazNCT05900258Written as Tirbanibulin
- Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate CancerCompletedPhase 2Athenex, Inc.NCT01074138Written as KX2-391
- Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male SubjectsCompletedPhase 1PharmaEssentiaNCT05245578Written as KX01 ointment 1%
- Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)CompletedPhase 1Kinex Pharmaceuticals Inc.NCT01397799Written as KX2-391
- A Study of KX2-391 With Paclitaxel in Patients With Solid TumorsStatus unknownPhase 1/2Hanmi Pharmaceutical Company LimitedNCT01764087Written as KX2-391 and Paclitaxel
- Evaluation of KX2-391 in Patients With Advanced MalignanciesCompletedPhase 1Athenex, Inc.NCT00658970Written as KX2-391
Codes
What other systems call tirbanibulin · ClinicalTrials.gg INT001552
- MeSH (NLM) C000713668tirbanibulinOne source ClinicalTrials.gov
- UNII (FDA) 4V9848RS5GTIRBANIBULINConfirmed FDA, Wikidata
- RxNorm 2471078One source FDA
- Wikidata Q27888424tirbanibulinConfirmed FDA, Wikidata
- NCI Thesaurus C74077TirbanibulinOne source FDA
- DrugBank DB06137One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000713668 | tirbanibulin | One source ClinicalTrials.gov |
| UNII (FDA) | 4V9848RS5G | TIRBANIBULIN | Confirmed FDA, Wikidata |
| RxNorm | 2471078 | — | One source FDA |
| Wikidata | Q27888424 | tirbanibulin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C74077 | Tirbanibulin | One source FDA |
| DrugBank | DB06137 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.